



The Netherlands | Recycled plastic pallets | www.cabka.com | August 23 2022

Closing share Price (22/08/2022) EUR 6.96 Target valuation range

#### EUR 9.00 - 12.00

Risk	Medium
Reuters	CABKA-AMS
Bloomberg	CABKA NA
Shares number (m)	24.37
Market cap. (m)	170
Net debt 12/21 (m)	54
Net debt/EBITDA 12/21	2.05
1 year price perf.	-30.4%
Diff. with Euro Stoxx	-17.1%
Volume (sh./day)	4,473
H/L 1 year	11.75 - 6.88
Free Float	42.7%
RAM.ON Finance	45.8%
Sponsors	5.6%
Eikenbosch	4.3%
Key Employees	1.6%

#### **Company description**

Cabka produces pallets and large containers made from mainly recycled plastic using proprietary technology. It also manufactures eco products for gardening and transportation, made entirely out of recycled plastic.



#### Analyst:

1

#### Luuk van Beek

Senior Equity Analyst +31 20 573 5471 I.vanbeek@degroofpetercam.com

#### Cabka

#### Reinforcing its positions despite short term volatility

This report is considered as a marketing communication. It has been commissioned and paid for by Cabka and has not been prepared in accordance with legal requirements designed to promote the independence of investment research, and is also not subject to any prohibition on dealing ahead of the dissemination of investment research.

#### Some headwinds in H1

- Cabka's H1 results were affected by a delay in passing on input price increases, and a temporary shutdown of the ECO plant. We expect that it can fully pass on the higher input costs from H2-22 on, but there will still be a mathematical dilutive margin effect as long as costs remain at current elevated levels.
- The US plant in Hazelwood is out of service due to a flood, but the company has been able to secure sufficient capacity elsewhere to cover 70% of its pre-flood level. That will allow it to deliver to its key customers, including the important new contract with Target.
- We cut our Adj. EBITDA estimate by 25% for 2022 and 10% for 2023 to reflect these effects.

#### Valuation range cut to EUR 9.00-12.00

We cut our target range from EUR 11-15.50 to EUR 9.00-12.00 to reflect the impact of the recent increase in interest rates on our DCF and our more cautious assumptions following the rising global volatility. We see the following drivers for an increase in Cabka's share price:

- **Confirmation of higher revenue growth.** We expect that Cabka can realize organic revenue growth at the high end or above its high single digit target in the next few years, thanks to strong demand and rising prices. That should create operating leverage and thus allow the company to realize double-digit Adjusted EPS growth.
- Acquisitions. Acquisitions of complementary companies can be an effective way to accelerate Cabka's growth. They can allow the company to quickly expand its geographical coverage, while adding new products to its offering. Alternatively, they may enhance access to plastic waste, reinforcing its competitive advantage in raw material sourcing.
- Shift to ESG investing. Cabka is a clear frontrunner in circularity. We expect that
  this will attract the growing group of ESG-investors. However, we also expect
  non-ESG investors to increasingly value companies that are well prepared for
  future regulations regarding recycling and sustainability.

EUR	12/18	12/19	12/20	12/21	12/22e	12/23e	12/24e
Sales	156.9	160.6	134.6	170.6	208.5	233.4	252.6
EBITDA	23.8	24.8	19.0	26.3	25.0	36.0	41.7
Adj. profit	2.7	1.2	-3.4	4.3	8.0	9.9	13.1
EPS	0.00	0.00	0.00	0.18	0.33	0.40	0.54
FCF/share	-	-	-	-	-0.50	-0.04	0.09
EV/EBITDA	-	-	2.8	2.1	8.0	5.7	5.0
Adj. P/E	-	-	nm	63.7	21.2	17.2	12.9
FCF Yield	-	-	-	-	-7.2%	-0.5%	1.3%
Div. Yield	-	-	0.0%	0.0%	2.2%	1.9%	2.5%

Source: Cabka/Degroof Petercam estimates



#### Increasing competitive advantage thanks to rising input prices

Rising input prices were a major theme in Cabka's H1-22 results. The costs of Cabka's key inputs, plastics and energy, have increased sharply over the past year (Exhibit 1). In response to this, Cabka implemented several rounds of price increases, leading to a 15% rise in price levels year-on-year. Despite this, it was able to grow volumes by 12%. In our view, this shows the company's strong competitive position in pallets and large containers. Virgin plastic prices roughly doubled, but prices for the recycled material that Cabka uses rose much less (see Exhibit 1). Cabka uses 87% recycled materials, versus a European average of only 14%. Furthermore, the company benefited from its backward integration, which protected it from the scarcity of raw materials that affected others. Also versus other materials Cabka's competitive position improved. The price increase for wooden pallets was much higher than for plastic, due to the sharp rise in lumber prices.

Customers do not switch immediately from other materials to plastic when there is a price differential because that requires readjustment of their supply chains. However, the growing importance of using re-usable packaging is leading to increased customer interest for Cabka's products and the price advantage of its plastic products is an additional trigger for them to make the switch. We therefore expect that the current situation will further reinforce Cabka's market position.



Cabka has passed on the cost increases to customers, but in H1-22 there was a EUR 1.3m negative impact on profitability caused by the delay in passing theseon. Management is changing its new contracts so that it can pass on future price increases more quickly based on indexation. It has implemented an additional 5% price increase per August 1, bringing pricing in line with current cost levels provided that input costs remain around current levels.

In H1 Cabka still managed to achieve gross profit growth in line with the overall volume growth of 12%. The fact that it increased prices only with the absolute amount of the additional raw material costs, without any additional profit margin meant that there was a (mathematical) dilutive effect on the gross margin (Exhibit 2) and EBITDA-margin (Exhibit 3). The reported EBITDA-margin was also affected by costs for the IPO (EUR 3.2m), employee option plan (EUR 1.4m) and restructuring (EUR 0.5m).



Exhibit 2

52

50

48

46

44

42

40

38

Source: Degroof Petercam estimates



#### Hazelwood Flood limits near-term US contribution

Cabka's US plant in Hazelwood was hit by a flood after extreme rainfall on July 27. As a result, the company was forced to shut down the plant, and it does not expect to be able to restart production in the short term. However, it has been able to recover all essential injection moulding tools. It has also secured external production capacity allowing it deliver 70% of the sales level it had before the flood. This allows it to execute the important new framework contract with Target (first order: EUR 13m, many more expected) and continue deliveries to its key customers. Management is still looking for additional capacity, so that it can further increase its production levels.

Source: Degroof Petercam estimates

This is a clear setback, as the company was on a strong growth trajectory in the United States. The outsourcing of production will have a negative impact on margins, which may be partly offset by a mix shift towards the most profitable products as Cabka prioritize its strategic customers and is likely to cut primarily into its low-end product sales.

There is no visibility on a restart of production at Cabka's own plant. We expect that it will use this event to rethink its production setup for the US market. In general, it is looking to shift production of its standardized products to tollers, while reserving its own production capacity to produce high value-added customized products. In the medium term that should allow the US activities to realize higher margins. Thanks to the quick response of management, it believes it should be able to achieve H2 sales above the H1 level in the US, with the first deliveries on the Target contract as a key contributor.

#### Dip in Eco-products in H1

During H1, Cabka consolidated the production of its ECO-products on its site in Weira, closing the facilities in Genthin (both in Germany). That led to a temporary production closedown in Q2 and EUR 0.8m in missed revenues. Production has started up again in June. The new setup brings higher efficiency and a 25-30% increase in production capacity. This will allow the company to grow revenues from this segment further, especially in view of the healthy demand.



### Cuts in EBITDA to reflect more volatile markets

Management has reiterated its target to move to an EBITDA-margin above 20% in the mid-term. However, it now adds that the "relative EBITDA is subject to inflationary developments". If input prices remain structurally 10% higher than when the company announced its targets, that would mathematically lead to a dilution from 20% to 18.2%.

On balance, we cut our Adj. EBITDA estimate by 25% for 2022 to reflect the shutdown of the ECO plant in Q2, the impact of the flood in the US and the more volatile market environment. We expect the latter two factors to also have an effect in 2023, and we cut our estimate for that year by 10%. For 2022, the impact on our Adjusted EPS estimate is largely offset by a smaller net costs for taxes and warrants. We cut our 2023 Adj. EPS estimated by 18%.







#### Valuation

We based our valuation range on a DCF-analysis and a peer group comparison, both of which indicate significant upside.

#### DCF indicates significant upside

For our DCF analysis, we forecast 7.6% average revenue growth during the forecast period, in line with the mid-term target of high single digit growth. The average EBITDA-margin of 18.4% during this period is below the target of at least 20% because we include the dilutive margin effect of the recent price increases. Adjusting for the price increase since Cabka set the target, we still expect it to meet this goal. Our estimated capex is 22% above depreciation, reflecting expansion capex in combination with the company's asset-light strategy using contract manufacturers. Our perpetual value is based on 2% growth and a ROCE of 12%. We have raised our WACC from 7.7% to 8.2% to reflect the recent increases in interest rates. Using these assumptions, we arrive at a value of EUR 10.40 per share.

Exhibit 6 shows a sensitivity analysis for different assumptions on the WACC and ROCE, including the potential impact of dilution from performance shares, warrants and other instruments. For this adjustment we use a conservative approach. We assume that if the target value without dilution adjustment is above the conversion price, the instrument will be converted immediately. In reality, the conversion will only take place if the share price is above this level for 15 days during a consecutive 30-day period. It will also take place in stages, and part of the instruments may lapse before they are executed. For our target valuation range, we use a WACC of 9.2% for the bottom and 7.2% for the top, leading to a range of EUR 8.3 to EUR 12.



mln euros	2023e	2024e	2025e	2026e	2027e	2028e	2029e	2030e	2031e	2032e >	2032e	Total
Revenues	233	253	270	289	309	331	354	379	406	434		
EBIT	15	20	25	29	32	37	39	42	46	50		
Depreciation & amortization	21	22	23	25	26	28	30	31	33	34		
Change in provisions	-	-	-	-	-	-	-	-	-	-		
Change in working capital	-6	-6	-4	-5	-5	-5	-6	-6	-6	-7		
Taxes	-5	-6	-8	-9	-10	-11	-12	-13	-14	-15		
Associates & other	-	-	-	-	-	-	-	-	-	-		
Capex	-22	-24	-26	-27	-29	-31	-34	-34	-34	-30		
Capex intangibles	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0		
Finance Lease	-3	-3	-3	-3	-3	-3	-4	-4	-4	-4		
Acquisitions & other investment	-	-	-	-	-	-	-	-	-	-		
Free cash flow	-1	2	7	9	11	13	14	17	20	28	488	
Discount factor	1.07	1.15	1.25	1.35	1.46	1.58	1.71	1.85	2.00	2.16	2.34	
Discounted FCF	-0.9	2.0	5.7	6.5	7.2	8.0	8.0	9.0	9.9	12.7	208.3	276.4
Revenue change	+12.0%	+8.2%	+7.0%	+7.0%	+7.0%	+7.0%	+7.0%	+7.0%	+7.0%	+7.0%	+2.0%	,
EBITDA-margin	15.4%	16.5%	17.9%	18.4%	18.9%	19.4%	19.4%	19.4%	19.4%	19.4%	19.4%	
EBITDA-margin pre IFRS16	14.2%	15.3%	16.8%	17.3%	17.8%	18.4%	18.4%	18.4%	18.4%	18.5%	18.5%	
EBIT-margin	6.5%	7.8%	9.3%	9.9%	10.5%	11.0%	11.1%	11.1%	11.2%	11.5%	11.5%	
ROCE	7.3%	8.9%	10.5%	11.0%	11.4%	11.8%	11.6%	11.4%	11.4%	11.5%	12.0%	<b>•</b>
Risk free rate	1.68%	I	Equity (m	arket va	lue)	75.0%			Enterprise	e value		276.4
Estimated Beta	1.00	I	Net debt			25.0%			Net Debt e	excl.lease	:	-22.5
Market risk premium	8.0%								Minoritie	s		-0.2
Cost of equity	9.7%	,	WACC			8.2%			Other ass <b>Equity val</b>			۔ 253.7
Long-term interest rate	5.0%								Equity vai	ue		255.7
Marginal tax rate	27.6%	1	Perpetual	growth		2.0%			# of share	S		24.4
Cost of debt	3.6%	1	ROCE afte	r 2032		12.0%			DCF per s	hare		€ 10.4
									DCF includ	ling dilutio	on	€ 10.4
									Current sl	nare price		€ 6.96
									Upside			+50%

#### DCF sensitivity analysis Exhibit 6 WACC 10.2% 6.2% 11.2% 9.2% 8.2% 7.2% 5.2% 8.0% 6.3 7.7 9.6 11.6 14.1 18.9 5.2 10.0% 6.6 8.1 10.1 20.0 ROCE 5.5 12.2 15.0 12.0% 6.8 8.3 20.8 10.4 12.0 15.5 5.7 14.0% 5.8 7.0 8.5 10.7 12.3 15.5 21.3 16.0% 8.7 10.8 15.8 5.9 7.1 12.5 21.7 Source: Degroof Petercam estimates



#### Discount to peer group EV/EBITDA

For the peer group (Exhibit 7), we use three companies that are also active in industrial plastic packaging (Berry, Greif and Myers) and three companies that operate in waste management and recycling (Biffa, Cleanaway, and Renewi). This reflects the fact that Cabka is active in both the recycling of plastic waste and the production of plastic pallets and large containers. Cabka currently trades at a discount to the peer group on EV/EBITDA. If apply the peer group average multiple to Cabka's 2023 EBITDA, we arrive at a value of EUR 9 per share. However, we believe that it deserves a significant premium on this peer group because of its unique capability to offer a fully circular product. Together with a widening product range and geographic coverage that should allow it to show much faster growth. Its unique sourcing capabilities should also give it an advantage on input costs. Using a premium of 30% leads to a valuation of EUR 12 per share, taking into account dilution.

#### Exhibit 7 Peer group comparison

	Price		P/E			EV/Sales EV/EBIT			V/EBITDA	BITDA EV/EBIT			
	22-Aug-22	2022	2023	2024	2022	2023	2024	2022	2023	2024	2022	2023	2024
Plastic Industrial Packaging													
Berry (US)	56.96	7.4	7.1	6.6	1.0	1.0	0.9	6.9	6.6	6.1	10.5	9.4	8.3
Greif (US)	70.74	8.9	9.5	N.M.	0.8	0.8	N.A.	5.8	5.6	N.A.	8.2	7.6	N.A.
Myers Industries (US)	21.14	13.4	11.1	9.7	1.0	0.9	0.8	8.1	6.4	5.4	10.5	8.2	6.8
Waste Management and Rec	ycling												
Biffa (UK)	3.99	N.M.	19.5	17.5	1.3	1.2	1.1	8.7	8.1	7.5	17.3	15.6	14.5
Cleanaway (AUS)	2.69	36.5	29.9	25.6	2.4	2.3	2.2	11.8	10.8	10.3	26.2	22.0	20.4
Renewi (UK)	8.22	8.9	8.7	7.5	0.7	0.7	0.7	5.4	5.2	4.9	10.3	9.2	9.0
Average		15.0	14.3	13.4	1.2	1.1	1.1	7.8	7.1	6.8	13.8	12.0	11.8
Median		8.9	10.3	9.7	1.0	0.9	0.9	7.5	6.5	6.1	10.5	9.3	9.0
Cabka (NL)	6.96	21.2	17.2	12.9	1.0	0.9	0.9	8.4	6.0	5.2	34.5	14.3	11.0
Vs peer average		+41.1%	+20.4%	-3.6%	-16.3%	-19.1%	-25.2%	+7.7%	-16.1%	-23.8%	+149.4%	+18.8%	-6.5%
Vs peer median		+138.1%	+66.8%	+32.5%	+1.2%	-0.9%	-8.0%	+12.0%	-8.4%	-14.3%	+228.8%	+53.7%	+23.1%
Source: Degroof Peterca	mostimato	/Ploomh	ora										

Source: Degroof Petercam estimates/Bloomberg

#### Drivers for the share price

We cut our target range from EUR 11-15.50 to EUR 9.00-12.00 based on our updated assumptions. Our new target range is lower than the previous one because of impact of the recent increase in interest rates on our DCF and our more cautious assumptions following the rising global volatility. Note that our valuation does not include the additional value Cabka can create by using its strong balance sheet for acquisitions.

We see the following drivers for an increase in Cabka's share price:

- **Confirmation of higher revenue growth.** We expect that Cabka can realize organic revenue growth at the high end or above its high single digit target in the next few years, thanks to strong demand and rising prices. That should create operating leverage and thus allow the company to realize double-digit Adjusted EPS growth.
- Acquisitions. Acquisitions of complementary companies can be an effective way to accelerate Cabka's growth. They can allow the company to quickly expand its geographical coverage, while adding new products to its offering. Alternatively, they may enhance access to plastic waste, reinforcing its competitive advantage in raw material sourcing.
- Shift to ESG investing. Cabka is a clear frontrunner in circularity. We expect that this will attract the growing group of ESG-investors. However, we also expect non-ESG





investors to increasingly value companies that are well prepared for future regulations regarding recycling and sustainability.



Profit & Loss (EUR m)	12/18	12/19	12/20	12/21	12/22e	12/23e	12/24e
Revenues	162.6	169.7	138.8	177.7	214.7	239.8	259.2
(of which Sales)	156.9	160.6	134.6	170.6	208.5	233.4	252.6
(Y/Y - %)	13%	2%	-16%	27%	22%	12%	8%
(of which Other revenues)	5.7	9.1	4.2	7.0	6.2	6.4	6.6
Cost of goods sold	-81.0	-85.5	-64.5	-89.5	-117.6	-127.5	-137.4
Gross profit	81.6	84.2	74.3	88.2	97.1	112.4	121.8
Personnel costs	-33.0	-34.4	-31.1	-33.1	-41.5	-45.5	-48.0
Other costs	-	-	-	-	-	-	-
EBITDA	23.8	24.8	19.0	26.3	25.0	36.0	41.7
EBITA	8.2	7.0	0.7	9.6	6.1	15.1	19.7
(Ebita margin - %)	5.3%	4.4%	0.6%	5.6%	2.9%	6.5%	7.8%
Amortization	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Impairment	-	-	-	-	-	-	-
EBIT	8.2	7.0	0.7	9.6	6.1	15.1	19.7
Net Financial Result	-2.2	-3.6	-2.3	-1.9	1.6	-1.4	-1.4
(of which Net interest charges)	-2.2	-3.6	-2.3	-1.9	1.6	-1.4	-1.4
(of which Other)	-	-	-	-	-	-	-
Pre-tax result	6.0	3.5	-1.6	7.7	7.6	13.7	18.3
Taxes	-3.2	-2.2	-1.6	-3.0	-2.1	-3.8	-5.0
Associates	-	-	-	-	-	-	-
Minorities	-0.1	0.0	-0.2	-0.3	-0.1	-0.1	-0.1
Net earnings excl. exceptionals	-	-	-	-	-	-	-
Except. / Discont. operations	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net declared earnings	2.7	1.2	-3.4	4.4	5.4	9.9	13.1
Net adjusted earnings	2.7	1.2	-3.4	4.3	8.0	9.9	13.1
Cash Flow (EUR m)	12/18	12/19	12/20	12/21	12/22e	12/23e	12/24e
EBIT	8.2	7.0	0.7	9.6	6.1	15.1	19.7
Depreciation	15.6	17.8	18.2	16.7	18.9	20.9	22.0
Amortization	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Impairment	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Changes in provision	0.1	1.1	0.4	2.3	0.0	0.0	0.0
Changes in working capital	-1.4	-2.6	0.4	-6.0	-12.6	-6.4	-5.6
Others	-1.4	0.0	0.2	0.0	0.0	-0.4	0.0
Operational Cash Flow	21.4	<b>23.4</b>	<b>20.4</b>	22.7	<b>12.3</b>	<b>29.7</b>	<b>36.1</b>
Tax expenses	-1.5	-1.1	-2.6	-3.9	-2.1	-3.8	-5.0
Dividends from associates	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net interest charges	-1.4	-3.1	-2.1	-1.9	1.6	-1.4	-1.4
Others	0.0	0.0	0.0	0.0	0.0	0.0	-1.4
	<b>18.5</b>	<b>19.1</b>	15.6	16.9	11.8	<b>24.5</b>	<b>29.7</b>
CF from operating activities							
CAPEX	-26.0	-13.9	-12.4	-16.5	-20.8	-22.2	-24.0
Investments in intangibles	-0.3	-0.6	-0.1	-0.4	-0.3	-0.3	-0.3
Acquisitions	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Divestments	0.2	0.3	4.1	1.1	0.7	0.0	0.0
Others	0.5	0.0	0.0	0.0	0.0	0.0	0.0
CF from investing activities	-25.6	-14.1	-8.5	-15.8	-20.5	-22.5	-24.3
Dividend payment	0.0	0.0	0.0	0.0	0.0	-3.7	-3.3
Minor. & pref. dividends	0.0	0.0	-0.2	-0.3	-0.1	-0.1	-0.1
Equity financing	0.0	0.0	0.0	0.0	43.3	0.0	0.0
Others	0.1	0.1	0.0	0.0	-2.9	-3.0	-3.1
CF from financing activities	0.1	0.1	-0.2	-0.3	40.3	-6.7	-6.4
Changes in consolidation scope	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Exchange rate impact	-0.4	-0.2	0.8	0.0	0.0	0.0	0.0
Net debt/cash change	7.5	-4.9	-7.8	-0.7	-31.6	4.7	1.1
FCF to Enterprise FCF to Equity	-4.9 -7.8	8.9 4.7	7.8 3.1	5.7 -0.1	-11.7 -12.3	4.2 -0.9	8.7 2.3

# Solution Degroof Petercam

Balance Sheet (EUR m)	12/18	12/19	12/20	12/21	12/22e	12/23e	12/24e
Fixed assets	79.6	76.1	65.5	66.0	87.6	92.1	97.5
Tangible fixed assets	76.9	73.9	64.3	65.3	78.1	82.3	87.4
Goodwill	0.0	0.1	0.1	0.1	0.0	0.0	0.0
Other intang. assets	2.6	2.0	1.0	0.5	0.9	1.2	1.5
Financial fixed assets	0.1	0.1	0.1	0.1	8.6	8.6	8.6
Other fixed assets	-	-	-	-	-	-	-
Current assets	57.3	73.6	58.6	75.5	106.8	113.8	122.4
Inventories	25.8	30.3	25.2	31.1	41.7	45.5	49.3
Trade receivables	21.5	20.1	20.5	27.1	32.3	37.3	40.4
Other current assets	3.3	3.8	3.8	7.3	10.2	11.1	11.9
Cash & Equivalents	6.8	19.5	9.2	10.0	22.5	19.8	20.8
Discontinued assets	-	-	-	-	-	-	-
Total assets	136.9	149.7	124.1	141.5	194.4	205.9	219.9
Total Equity	36.9	38.3	33.8	38.6	82.4	88.6	98.5
Equity	35.9	37.3	33.4	38.5	82.2	87.4	96.3
Minorities & preferred	1.0	0.9	0.4	0.1	0.2	1.2	2.2
Provisions	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Provisions for pensions	-	-	-	-	-	-	-
Deferred taxes	-	-	-	-	-	-	-
Other provisions	-	-	-	-	-	-	-
Other LT liabilities	6.6	7.7	7.2	8.7	1.8	1.8	1.8
LT interest bearing debt	0.0	0.0	0.0	0.0	40.5	41.5	42.5
Current liabilities	93.4	103.8	83.1	94.2	71.6	75.9	79.0
ST interest bearing debt	68.7	79.5	62.5	64.0	21.4	22.4	23.4
Accounts payables	19.9	20.8	15.2	25.4	37.5	40.9	42.9
Other ST liabilities	4.8	3.5	5.4	4.8	12.7	12.7	12.7
Discontinued liabilities	-	-	-	-	-	-	-
Total liabilities	136.9	149.7	124.1	141.5	194.4	205.9	219.9
EV and CE details (EUR m)	12/18	12/19	12/20	12/21	12/22e	12/23e	12/24e
Market cap.	-	-	0.0	0.0	169.6	169.6	169.6
+ Net financial debt	62.0	60.0	53.3	54.0	39.4	44.0	45.1
(of which LT debt)	0.0	0.0	0.0	0.0	40.5	41.5	42.5
(of which ST debt)	68.7	79.5	62.5	64.0	21.4	22.4	23.4
(of which Cash position)	6.8	19.5	9.2	10.0	22.5	19.8	20.8
+ Provisions (pension)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
+ Minorities (MV)	1.0	0.9	0.4	0.1	0.2	1.2	2.2
<ul> <li>Peripheral assets (MV)</li> </ul>	-0.1	-0.1	-0.1	-0.1	-8.6	-8.6	-8.6
+ Others	-	-	-	-	-	-	-
Enterprise Value	-	-	53.6	54.0	200.6	206.3	208.4
Equity (group share)	35.9	37.3	33.4	38.5	82.2	87.4	96.3
+ Net financial debt	62.0	60.0	53.3	54.0	39.4	44.0	45.1
+ Provisions (pension)	-	-	-	-	-	-	-
+ Minorities	1.0	0.9	0.4	0.1	0.2	1.2	2.2
- Peripheral assets	-0.1	-0.1	-0.1	-0.1	-8.6	-8.6	-8.6
	-		0.0	0.0	0.0	0.0	0.0
•	-	0.0					
+ Others	- 98.7	0.0 <b>98.2</b>	87.0	92.5	113.1	124.0	135.0
+ Others Capital employed (for ROCE) + Accumulated goodwill amortiz.		98.2 0.0		<b>92.5</b> 0.0	<b>113.1</b> 0.0	<b>124.0</b> 0.0	<b>135.0</b> 0.0



Per Common Share (EUR)	12/18	12/19	12/20	12/21	12/22e	12/23e	12/24e
Adjusted EPS (*)	0.00	0.00	0.00	0.18	0.33	0.40	0.54
Adjusted EPS (fully diluted)	-	-	-	-	-	-	-
Declared EPS	0.00	0.00	0.00	0.18	0.22	0.40	0.54
CFS	0.00	0.00	0.00	0.00	1.00	1.26	1.44
FCF (to Equity)	-	-	-	-	-0.50	-0.04	0.09
Dividend	0.00	0.00	0.00	0.00	0.15	0.13	0.18
Book Value	0.00	0.00	0.00	0.00	3.37	3.59	3.95
Shares (m)							
At the end of F.Y.	0.000	0.000	0.000	0.000	24.375	24.375	24.375
Average number	0.000	0.000	0.000	0.000	24.387	24.375	24.375
Fully diluted Average number	0.000	0.000	0.000	0.000	28.566	28.566	28.566
(*) Adjusted EPS : pre-goodwill amortisat	ion earnings, adju	sted for post	-tax non-recu	rrent items			
Ratios	12/18	12/19	12/20	12/21	12/22e	12/23e	12/24e
Valuation analysis							
P/E	-	-	nm	63.7	21.2	17.2	12.9
P/CF	-	-	nm	nm	7.0	5.5	4.8
P/BV	-	-	nm	nm	2.1	1.9	1.8
EV/Sales	-	-	0.4	0.3	1.0	0.9	0.8
EV/EBITDA	-	-	2.8	2.1	8.0	5.7	5.0
EV/EBITA	-	-	71.6	5.6	33.0	13.7	10.6
EV/EBIT	-	-	71.6	5.6	33.0	13.7	10.6
EV/CE	-	-	0.6	0.6	1.8	1.7	1.5
EV/CE (grossed goodwill)	-	-	0.6	0.6	1.8	1.7	1.5
EV/FCF (1)	-	-	6.9	9.5	-17.1	49.0	23.9
FCF yield (2)	-	-	-		-7.2%	-0.5%	1.3%
Dividend yield	-	-	0.0%	0.0%	2.2%	1.9%	2.5%
Financial ratios	a =						
Interest cover	3.7	2.0	0.3	4.9	-3.8	11.2	14.0
Net Debt/EBITDA	2.6	2.4	2.8	2.1	1.6	1.2	1.1
Net Debt/Equity Net Debt/FCF (2)	168.1% -7.9	156.8% 12.9	157.7% 17.3	140.1% -409.4	47.8% -3.2	49.7% -48.1	45.8% 19.8
Capital turnover	-7.9	12.9	17.5	-409.4 1.8	-5.2	-48.1	19.8
ROCE pre-tax	8.3%	7.1%	0.9%	10.4%	5.4%	12.2%	14.6%
ROCE post-tax	8.3%	7.1%	0.9%	10.4%	5.4%	12.2%	14.6%
ROCE pre-tax (grossed goodwill)	8.3%	7.1%	0.9%	10.4%	5.4%	12.2%	14.6%
ROCE post-tax (grossed goodwill)	8.3%	7.1%	0.9%	10.4%	5.4%	12.2%	14.6%
ROE	7.9%	3.4%	-9.6%	12.1%	9.0%	11.6%	14.3%
Working capital (in % of sales)	17.5%	18.4%	22.6%	19.3%	17.5%	18.0%	18.5%
DSO (days)	49.5	47.3	55.0	50.9	52.0	54.5	56.2
Average payment period (days)	47.4	46.3	48.9	43.4	55.1	61.3	60.5
Inventory turn (days)	-	-	-	-	-	-	-
Payout	-	-	-	-	45.7%	33.0%	32.5%
Margin analysis and tax rate							
Gross margin	50.2%	49.6%	53.5%	49.6%	45.2%	46.9%	47.0%
EBITDA margin	15.2%	15.5%	14.1%	15.4%	12.0%	15.4%	16.5%
EBITA margin	5.3%	4.4%	0.6%	5.6%	2.9%	6.5%	7.8%
Adjusted profit margin	1.7%	0.8%	-2.5%	2.5%	3.8%	4.2%	5.2%
Tax rate	53.1%	63.1%	-101.7%	39.0%	28.0%	27.5%	27.5%
Growth analysis							
Sales	13%	2%	-16%	27%	22%	12%	8%
EBITDA	32%	4%	-24%	39%	-5%	44%	16%
EBITA	101%	-15%	-89%	1185%	-37%	148%	31%
Adjusted profit	+chg	-55%	-chg	+chg	87%	23%	33%
Adjusted EPS	-	-	-	+chg	87%	23%	33%
Dividend	-	-	-	-	+chg	-11%	31%
(1) Based on ECE to Enterprise - (2) Based					00		02/0

(1) Based on FCF to Enterprise - (2) Based on FCF to Equity

**Notes** Source: company statements, 'e' indicates Degroof Petercam estimates





#### **Commissioned Research**

Degroof Petercam is commissioned by this company to publish research and is paid for this service.

#### Disclosures applicable when indicated on the front page

- 1. Degroof Petercam acts as a liquidity provider for this company and is paid for these services.
- 2. Degroof Petercam has provided corporate finance services in the past 12 months for this company.

#### General disclaimer

#### About Degroof Petercam

This report has been prepared by Bank Degroof Petercam SA/NV ("Degroof Petercam").

Degroof Petercam is a financial institution authorised by and under the prudential supervision of, as a credit institution, the National Bank of Belgium and under the supervision of the Financial Services and Markets Authority. It has its registered office at 44, rue de l'Industrie, 1040 Brussels and is registered with the crossroads bank for enterprises under number 0403.212.172.

#### No investment research

This report is considered as a marketing communication. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research, and it is not subject to any prohibition on dealing ahead of the dissemination of investment research.

#### Not approved by the competent regulator

This report is not subject to any statutory prior approval requirement by a competent supervisory authority. As a result, this report has not been, and will not be submitted for approval to any competent supervisory authority.

#### Content of the report

This report has been prepared by the sell-side research team of Degroof Petercam. All opinions, views, estimates and projections included herein reflect the personal views of the author on the subject company and related securities as of the date of this report. This report does not necessarily reflect the views of Degroof Petercam as institution and is subject to change without notice. The analyst(s) claim(s) furthermore not to have any meaningful financial interest in any of the aforementioned companies, not to be conflicted and not to have accepted any inducement from any person with a material interest in the subject company of the report at hand. The remuneration of the analysts is subject to the remuneration policy of Degroof Petercam and can be consulted here.

The information and opinions contained in this report have been compiled or arrived at from sources believed to be reliable and in good faith, but no representation or warranty, express or implied, is made as to their accuracy, completeness or correctness.

#### Validity of the report

Any information, opinion or estimate contained in the present report is, regardless of source, given in good faith and may only be valid as of the date on which this report is published and is subject to change. The value of any investment may also fluctuate as a result of market changes. Degroof Petercam is not obliged to inform the recipients of this report of any change to such opinions or estimates.

#### Not for retail clients

This report is meant exclusively for professional clients or eligible counterparties (as defined in the Markets in Financial Instruments Directive 2014/65/EU) and is not intended for retail clients use.

#### Review by the subject company of this report

Degroof Petercam reserves the right to submit a draft of the research report (excluding – where relevant - the target valuation range/fair value and the recommendation) for review to the subject company with the sole purpose of correcting any inadvertent material factual inaccuracies.

#### **Conflict of interest**

It should be noted that Degroof Petercam and the subject company have entered into an agreement relating to the production of this report. Degroof Petercam has received a remuneration from the subject company for the drafting and dissemination of this report. This remuneration is (i) a fixed fee which has been agreed between the subject company and Degroof Petercam prior to the drafting and publication of this report and (ii) under no circumstances positively or negatively influenced by the content of this report.

Due to the broad activities of the group to which Degroof Petercam belongs, it may occur that Degroof Petercam or any of its affiliates:

- holds positions or effect transactions in the securities of the company mentioned herein or any member of its group;
- performs or seeks to perform investment banking services for such companies (such as corporate finance advice services);
- acts as a market maker or a liquidity provider for the securities of the company mentioned herein;
- performs any other services it is legally entitled to provide;
- hold a mandate in the subject company;
- hold a significant stake in the subject company.

In this regard, Degroof Petercam is required to have arrangements in place to identify, prevent and manage conflicts of interest between itself and clients and between different clients. Degroof Petercam operates in accordance with a conflicts of interest policy under which Degroof Petercam has identified those situations in which there may be a conflict of interest and, in each case, the steps taken to manage that conflict. Degroof Petercam has taken reasonable care to ensure that objectivity of this research report and the independence of the author are ensured and it has put in place several arrangements (such as internal policies and procedures) in order to manage potential conflicts of interests. Degroof Petercam has for example implemented





a remuneration policy, a personal account dealing procedure and several organizational measures such as Chinese Walls which are designated to prevent against the wrongful disclosure and use of confidential and sensitive information. Where the arrangements under our conflicts of interest policy are not sufficient to manage a particular conflict, Degroof Petercam will inform the relevant client of the nature of the conflict so that the client can make a wellinformed decision. Next to the aforementioned arrangements, Degroof Petercam has also implemented the internal arrangements required by article 37(1) of the Commission Delegated Regulation 2017/565.

#### No offer

This report does not constitute and should not be construed as, an offer or solicitation for the sale, purchase or subscription of any financial instrument. Any offer or entry into any transaction requires Degroof Petercam's subsequent formal agreement which may be subject to internal approvals and execution of binding transaction documents.

#### No investment advice

The information contained in this report should not be regarded as personalized and should not be considered as a recommendation of investment advice. Recipients should not construe the content of this report as legal, tax, accounting or investment advice or personal recommendation. Accordingly Degroof Petercam is under no obligation to, and shall not, determine the suitability for the recipient of any potential transaction described herein. Recipients should seek advice to their advisors in order to determine the merits, terms, conditions and risks of any potential transaction that may be described herein.

#### Forward looking statements

This report may contain forward-looking statements. These forward-looking statements are subject to risks, uncertainties and assumptions and other factors that could cause the actual results, condition, performance, prospects, growth or opportunities to differ materially from those expressed in, or suggested by, these forward-looking statements. Forward-looking statements are not guarantees of future performance and there is no guarantee that any of the estimates or projections will be achieved. Actual results may vary from the projections and such variation may be material.

#### Past & simulated past performance

Any past or simulated past performance including back-testing, modelling or scenario analysis contained herein is no indication as to future performance. No representation is made as to the accuracy of the assumptions made within, or completeness of, any modelling, scenario analysis or back-testing.

#### Valuation method

Our target valuation is generally based on a combination of valuation methods including DCF, SOTP, peer group comparison, historical ratio analysis and others. The outcome of these valuation methods is sensitive to both external factors (e.g. interest rates and market valuations) and assumptions we make (e.g. on sales growth, profitability, or valuation discounts). Be aware that even small changes in these elements can lead to large changes in target valuation. More information on the valuation method used for this company can be found in the reports published on <a href="https://www.degroofpetercam.com/en-be/commissioned-research">https://www.degroofpetercam.com/en-be/commissioned-research</a>

#### No liability

Degroof Petercam accepts no liability whatsoever for any direct or consequential loss or damage arising from any use of this report or its content. This report does not purport to give an exhaustive description of the financial instrument and of the issuer of the financial instrument it relates to. Although all reasonable care has been taken to ensure that the information in this report is accurate, neither Degroof Petercam, nor any of its affiliated companies, directors, advisors or employees can be held liable for any incorrect, incomplete or missing information, or for any direct or indirect damage, losses, costs, claims, liabilities or other expenses which would result from the use of, or reliance on, this report, except in case of willful misconduct or gross negligence. The information contained in this report has not been independently verified by any independent third party.

#### **Distribution restriction**

The present report is exclusively intended to professional clients and eligible counterparties, to the exclusion of retail clients. It may not be copied, reproduced, marketed or distributed in whole or in part for any purpose whatsoever without the prior written consent of Degroof Petercam.

The present report may not be taken or transmitted or distributed, directly or indirectly, outside of the EEA (but for the United Kingdom).

#### **Report completion and updates**

This report was first disseminated by Degroof Petercam on 23 August 2022 07:43 CET

Valuations are continuously reviewed by the analyst and will be updated and/or refreshed regularly. The rationale behind a change in target valuation will be explained in such a refresher/update.

An overview of the research published on this company can be found on our website: <u>https://www.degroofpetercam.com/en-be/commisioned-research</u> This website will also give you access to all of the commissioned research reports that have been disseminated during the preceding 12-month period.

This report has not been reviewed by the company prior to publication.

The report has been reviewed by Frank Claassen, Senior Equity Analyst.

## **Degroof Petercam Global Markets**

www.degroofpetercam.com

Nijverheidsstraat / Rue de l'Industrie 44 – 1040 Brussels De Entrée 238 A 7<sup>th</sup> floor – 1101 EE Amsterdam

#### Benoît Mortelmans +32 2 662 82 93

E	quity Research / Analysts		Sales	
Fernand de Boer	Retail/Food & Beverages	+31 20 573 5417	Anthony della Faille	+32 2 662 8724
Kris Kippers	Consumer Goods/Holdings	+32 2 287 9259	Laurent Pierret	+32 2 662 8654
Frank Claassen	Industrials	+31 20 573 5409		
Christophe Dombu Youta, PhD	Biotech/Healthcare	+32 2 287 9051	Equity Sales	5
Vivien Maquet	Telecom/Utilities/Real Estate	+32 2 662 8446	Simon Vlaminck	+32 2 662 8291
Inna Maslova	Real Estate	+32 2 662 8644	Damien Fontaine	+32 2 662 8287
Laura Roba	ESG/Medtech	+32 2 287 9276	Assia Adanouj	+32 2 662 8768
Michael Roeg	Technology	+31 20 573 5422	Piethein Leune	+31 20 573 5436
David Seynnaeve, PhD	Biotech/Healthcare	+32 2 287 9771	Jeroen Van Genuchten	+31 20 573 5428
Joren Van Aken	Holdings/Misc.	+32 2 662 8883	Beatrice Leysens - Assistant	+32 2 662 8262
Luuk van Beek	Energy/Engineering/Construction	+31 20 573 5471		
Herman van der Loos, CFA	Real Estate	+32 2 662 8304	Sales Tradin	g
			Veronique De Schoemaecker	+32 2 662 8280
Christel De Clerck	Support & Editing	+32 2 662 8302	Pieter De Moerloose	+32 2 662 8870
			Fabrice Faccenda	+32 2 662 8986
			Frédéric Lebrun	+32 2 287 9190
Corpo	orate Brokerage & Syndication		Fixed Income S	ales
Gert Potvlieghe	<b>U</b> .	+32 2 662 8289	An-Sofie Meirsschaut	+32 2 662 8665
Raymond de Wolff		+31 20 573 5414	Olivier Gigounon	+32 2 287 9184
Tineke Hosselaer	Corporate access	+32 2 662 8290	Lieven Krikilion	+32 2 287 9559
Charlotte Mertens	Corporate access	+31 20 573 5416	Sandra Timmermans	+32 2 662 8852
			Derivatives	
			Karim Marrakchi	+32 2 662 8940
			Eric Debeaud	+32 2 287 9827

Thierry De Wispelaere

+32 2 662 8674